ZBH vs. GEHC, PHG, SOLV, SNN, PEN, STVN, GKOS, BLCO, INSP, and NARI
Should you be buying Zimmer Biomet stock or one of its competitors? The main competitors of Zimmer Biomet include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), and Inari Medical (NARI). These companies are all part of the "medical equipment" industry.
Zimmer Biomet vs.
Zimmer Biomet (NYSE:ZBH) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.
Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.9%. GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. Zimmer Biomet pays out 21.6% of its earnings in the form of a dividend. GE HealthCare Technologies pays out 3.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
GE HealthCare Technologies has higher revenue and earnings than Zimmer Biomet. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.
Zimmer Biomet currently has a consensus price target of $124.15, indicating a potential upside of 11.54%. GE HealthCare Technologies has a consensus price target of $98.75, indicating a potential upside of 20.87%. Given GE HealthCare Technologies' stronger consensus rating and higher probable upside, analysts clearly believe GE HealthCare Technologies is more favorable than Zimmer Biomet.
88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 1.0% of Zimmer Biomet shares are held by insiders. Comparatively, 0.3% of GE HealthCare Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Zimmer Biomet has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, GE HealthCare Technologies has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
Zimmer Biomet received 878 more outperform votes than GE HealthCare Technologies when rated by MarketBeat users. Likewise, 67.06% of users gave Zimmer Biomet an outperform vote while only 61.90% of users gave GE HealthCare Technologies an outperform vote.
Zimmer Biomet has a net margin of 11.77% compared to GE HealthCare Technologies' net margin of 10.13%. GE HealthCare Technologies' return on equity of 25.74% beat Zimmer Biomet's return on equity.
In the previous week, Zimmer Biomet had 1 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 26 mentions for Zimmer Biomet and 25 mentions for GE HealthCare Technologies. Zimmer Biomet's average media sentiment score of 1.37 beat GE HealthCare Technologies' score of 1.33 indicating that Zimmer Biomet is being referred to more favorably in the media.
Summary
Zimmer Biomet beats GE HealthCare Technologies on 12 of the 20 factors compared between the two stocks.
Get Zimmer Biomet News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zimmer Biomet Competitors List
Related Companies and Tools
This page (NYSE:ZBH) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy ZBH Stock Free ZBH Stock Alerts